With your support, we have been able to fund outstanding research, leading toward cures and improved quality of life for children with cancer. Browse through more than 1,000 funded projects below.
Use the search tool to refine your results. You can also click on a heading to sort by project title, institution name, or year the grant was awarded. Click on the project title to read more information.
You can learn about ALSF's grant review process here.
ALSF Funded Research Projects
|Project Title||Institution / Principal Investigator(s)||Grant Type||Year||State|
|Targeting EZHIP as a therapeutic strategy for infantile ependymomas||University of Wisconsin - Madison / Peter Lewis, PhD||Innovation Grants||2021||Wisconsin|
|Role of H3.3-G34R mutation in pediatric high-grade glioma||University of Texas M.D. Anderson Cancer Center / Jian Hu, PhD||Innovation Grants||2021||Texas|
|Turning Killers into THINKers: TME Hostility-Impervious NK Cells for Treating Neuroblastoma and Sarcoma||Baylor College of Medicine / Robin Parihar, MD/PhD||'A' Award Grants||2021||Texas|
|Loss of ER-mitochondria contacts drives therapy resistance in neuroblastoma||Children's Hospital of Philadelphia / Michael Hogarty, MD||Innovation Grants||2021||Pennsylvania|
|Novel targeting approach for pediatric B-cell malignancies||Thomas Jefferson University / Christine Eischen, PhD||Innovation Grants||2021||Pennsylvania|
|Targeting CCAAT/enhancer binding proteins CEBPB and CEBPD in neuroblastoma||Columbia University / Darrell Yamashiro, MD/PhD||Innovation Grants||2021||New York|
|Targeting tumor associated macrophages in metastatic Ewing sarcoma (ES)||New York Medical College / Mitchell Cairo, MD||Innovation Grants||2021||New York|
|A leukemia organoid platform for dissection and targeting of tumor-niche interactions||Columbia Institute for Cancer Genetics / Adolfo Ferrando, MD/PhD||Innovation Grants||2021||New York|
|Phosphopeptides as shared targets for donor derived T cell therapy of AML||Memorial Sloan-Kettering Cancer Center / Richard O'Reilly, MD||Innovation Grants||2021||New York|
|IND-Enabling Studies for WNTinib, a Novel Selective Therapeutic for CTNNB1 Mutant Hepatoblastomas||Icahn School of Medicine at Mount Sinai / Ernesto Guccione, PhD & Josep Llovet, MD & Arvin Dar, PhD||Reach Grants||2021||New York|